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Abstract
Mosquito-borne chikungunya virus (CHIKV) is a positive-sense, single-stranded RNA virus from the genus Alphavirus, family
Togaviridae, which causes fever, rash and severe persistent polyarthralgia in humans. Since there are currently no FDA
licensed vaccines or antiviral therapies for CHIKV, the development of vaccine candidates is of critical importance.
Historically, live-attenuated vaccines (LAVs) for protection against arthropod-borne viruses have been created by blind cell
culture passage leading to attenuation of disease, while maintaining immunogenicity. Attenuation may occur via multiple
mechanisms. However, all examined arbovirus LAVs have in common the acquisition of positively charged amino acid
substitutions in cell-surface attachment proteins that render virus infection partially dependent upon heparan sulfate (HS), a
ubiquitously expressed sulfated polysaccharide, and appear to attenuate by retarding dissemination of virus particles in
vivo. We previously reported that, like other wild-type Old World alphaviruses, CHIKV strain, La Re´union, (CHIKV-LR), does
not depend upon HS for infectivity. To deliberately identify CHIKV attachment protein mutations that could be combined
with other attenuating processes in a LAV candidate, we passaged CHIKV-LR on evolutionarily divergent cell-types. A panel
of single amino acid substitutions was identified in the E2 glycoprotein of passaged virus populations that were predicted
to increase electrostatic potential. Each of these substitutions was made in the CHIKV-LR cDNA clone and comparisons of
the mutant viruses revealed surface exposure of the mutated residue on the spike and sensitivity to competition with the
HS analog, heparin, to be primary correlates of attenuation in vivo. Furthermore, we have identified a mutation at E2
position 79 as a promising candidate for inclusion in a CHIKV LAV.
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Introduction
In the last few years, considerable attention has been focused
upon mosquito-borne chikungunya virus (CHIKV); once a
relatively obscure member of the Alphavirus genus in the Togaviridae
family of enveloped, positive-sense RNA viruses [1–3]. In 2005, an
East African clade CHIKV strain emerged on the Indian Ocean
island of La Re´union that was maintained in a human-mosquito-
human transmission cycle and caused a massive outbreak of
CHIK fever [4]. Spread and/or re-emergence of CHIKV in
Indian Ocean areas, Asia, southern Europe, and most recently in
the Caribbean, in the following years has resulted in an estimated
four to six million cases of CHIK fever with painful, often chronic,
arthritides and an ongoing worldwide public health problem [3,5].
The future occurrence of autochthonous cases in the mainland
Americas seems inevitable with frequent travel-associated virus
introduction, and the likelihood of a resulting outbreak is predicted
to be high [6,7]. Thus, the need to develop therapeutics and
vaccine candidates for protection against this virus is ever more
urgent. A cell culture-adapted LAV (181/25) is available as an
investigational drug to at-risk researchers [8,9]. However, insuf-
ficient attenuation and consequent reactogenicity problems have
precluded its licensure for general use [8]. New strategies are
required to develop CHIKV LAVs combining a more refined
balance between attenuation and immunogenicity [10].
Like all members of the genus, CHIKV has an infectious, single-
stranded RNA genome of ,11 kb with a m7G 59 cap structure
and a 39 polyadenylated tail (reviewed by [11]). Within this
genome are encoded four non-structural (nsP1-4) and three
structural (C, 6K/E1 and pE2) proteins from two open reading
frames in the genomic and subgenomic RNAs, respectively
[12,13]. CHIKV virions have icosahedral symmetry, with a
glycoprotein shell enclosing the viral membrane and nucleocapsid
[14]. pE2 and E1 glycoproteins insert into the cell’s endoplasmic
reticulum as they are synthesized, forming heterodimers that
trimerize into the viral ‘spikes’ and envelop nucleocapsids,
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budding as virus particles from the cell’s plasma membrane [11].
pE2 is cleaved by host furin into E2 and a released E3 fragment
during egress to produce the mature, fusion-competent virions in
preparation for the next round of infection.
CHIKV isolates bind to cell surface receptors via E2 and fuse with
cell membranes by clathrin-independent, Eps15-dependent, endo-
cytosis via E1 [15]. The relationship between alphaviruses and their
receptors is a complex one with many questions still unanswered
and the identity of the receptor(s) utilized by wild-type isolates is still
elusive with the exception of C-type lections, DC-SIGN and L-
SIGN [16]. For many years, receptor identification was clouded by
the use of strains that had adapted to growth in cultured cells.
Fifteen years ago, we demonstrated that in vitro passage of the
prototypic Old World alphavirus, Sindbis (SINV), in different
laboratories had resulted in the accumulation of positively charged
mutations in the E2 glycoprotein, which dramatically improved the
virus-cell surface receptor interaction in vitro [17,18]. In the converse
experiment, Griffin and coworkers showed that in vivo passage in
immune-deficient mice of a laboratory SINV strain could select for
acquisition of negative charge and reduced heparan sulfate (HS)-
dependence in vitro [19,20]. Amino acid substitutions that increased
net positive charge in certain E2 regions could dramatically increase
per particle infectivity in cultured cells, dependent upon ionic
interaction with negatively charged, cell-surface HS chains
[17,19,21]. The following observations are of profound importance
to the current study and to the biology of Old World alphaviruses in
general: i) the substitution for positively charged residues in E2 that
confer enhanced, HS-dependent infectivity in vitro is a common
phenomenon amongst cell culture-passaged strains of SINV [17–
19,21], Ross River (RRV; [22]) and Semliki Forest (SFV; [23])
viruses; ii) these mutations can be selected within only a few serial
passages in vitro [17]; and iii) viruses whose in vitro infectivity is
enhanced by artificial HS attachment/entry are typically attenuat-
ed/avirulent in vivo from the natural infection route, at least in part
due to reduced level and/or duration of viremia [20,24].
We demonstrated recently that a wild-type CHIKV strain
(LR2006 OPY1), isolated during the La Re´union outbreak and
sequence-stabilized in cDNA clone form (CHIKV-LR; [25,26]),
exhibited no significant dependence upon HSPGs or other
glycosaminoglycans (GAGs) for infectivity in vitro [27]. In contrast,
the 181/25 CHIKV LAV candidate, derived by 18 serial passages
of wild-type CHIKV (strain 15561) in MRC-5 fibroblasts to
achieve attenuation [9], was highly dependent upon ionic
interaction with HS for infectivity [27]. We predicted that this
was due to an amino acid substitution at E2 position 82 [27],
which was subsequently shown by Weaver and coworkers to
attenuate both CHIKV-15561 and CHIKV-LR in vivo [28].
Here, we have exploited existing knowledge to deliberately select
for and identify a set of E2 mutations that confer HS-dependence
for infectivity by serial passage of wild-type CHIKV-LR on different
cell-types in vitro. Single amino acid mutations that became
predominant in the virus population within only five to ten passages
through mammalian or mosquito cells were predicted by compu-
tational modeling to alter the electrostatic profile of the E2
glycoprotein and increase net positive charge in two exposed
regions. By individual introduction of these mutations into CHIKV-
LR, we have identified a panel of E2 mutations that confer reduced
virulence in a murine model of musculoskeletal disease (MSD) and
associated these with particular aspects of dependence upon HS for
attachment/infectivity in vitro. In particular, we identified a novel
mutation at E2 position 79 that increased attenuation over the E2-
82R mutation present in the 181/25 LAV but did not diminish
immunogenicity or protective efficacy. The positions of the
attenuating mutations are clustered within two regions in the
three-dimensional structure of the alphavirus trimer-heterodimer
with the most attenuating mutated residues prominently exposed to
the exterior of the spike. Furthermore, mutations conferring the
greatest attenuation were associated with very small plaque size and
sensitivity to competition with the HS analog, heparin. We propose
this approach as an informed means to create mutant viruses and
utilize in vitro HS interaction phenotypes and structural modeling to
identify promising candidates for inclusion in CHIKV and other
arboviral LAVs.
Materials and Methods
Ethical statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
animal procedures were performed according to a protocol
approved by the Institutional Animal Care and Use Committee
of the University of Pittsburgh (Protocol 1001073).
Mice
Pregnant and 21 d old CD-1 (Charles River Laboratories), and
8 wk old STAT129 (Taconic Laboratories) mice were housed
under specific pathogen free conditions and all experiments were
conducted at ABSL-3.
Cell lines
BHK-21, CHOK1, pgsA745, pgsD677, and RAW264.7 cells
were cultured as previously described [27,29]. MC3T3-E1
osteoblasts were maintained in alpha minimum essential medium
(AMEM) supplemented with 10% fetal bovine serum (FBS), 1 mM
sodium pyruvate and 0.05 g/mL L-glutamine.
In vitro passage
CHIKV-LR virus stock was serially passaged 10 times in
triplicate series on CHOK1, pgsA745, or C6/36 cells, with a
1:100 dilution of progeny virions between passages. At P5 and P10
Author Summary
With the adaptation of chikungunya virus (CHIKV) to
transmission by the Aedes albopictus mosquito, a pandem-
ic has occurred resulting in four to six million human
infections, and the virus continues to become endemic in
new regions, most recently in the Caribbean. CHIKV can
cause debilitating polyarthralgia, lasting for weeks to years,
and there are currently no licensed vaccines or antiviral
therapies available. While an investigational live-attenuat-
ed vaccine (LAV) exists, problems with reactogenicity have
precluded its licensure. The purpose of the current study
was to: i) devise an in vitro passage procedure that reliably
generates a panel of CHIKV envelope glycoprotein
mutations for screening as vaccine candidates; ii) deter-
mine the position of the mutations in the three-dimen-
sional structure of the alphavirus spike complex and their
effect on electrostatic potential; iii) determine the atten-
uation characteristics of each mutation in a murine model
of CHIKV musculoskeletal disease; and iv) to identify in
vitro assays examining the dependency of infection upon
HS that correlate with attenuation and localization in the
glycoprotein spike. This approach provides a paradigm for
the rational design of future LAVs for CHIKV and other
mosquito-borne viruses, by deliberately selecting and
combining attenuating processes.
Toward Rational CHIKV Vaccine Design
PLOS Neglected Tropical Diseases | www.plosntds.org 2 February 2014 | Volume 8 | Issue 2 | e2719
supernatant from infected cells was placed in Tri Reagent-LS
(MRC) containing 5 mg of tRNA carrier, and total RNA was
extracted as per manufacture instructions. To sequence mutations
in E2, cDNA was generated using RT-PCR (Roche) with a specific
primer in the E1 gene, immediately downstream of the E2 gene 39
terminus (GCAGCCTCTTGGTATGTGGC), and the entire
pE2 gene was PCR amplified (S-CTAATGAAGGAGCCCG-
TACA; AS-GCAGCCTCTTGGTATGTGGC) using Deep Vent
polymerase (NEB). The PCR fragment was either directly
sequenced (Retrogen) or cloned into pCR-Blunt (Invitrogen) and
sequenced.
Viruses
pE2 gene mutations were introduced into the cDNA clone of
CHIKV-LR using the Quick Change II XL mutagenesis kit
(Stratagene). CHIKV-LR reporter viruses were created by
inserting a cleavable in-frame fusion between capsid and E3 using
Quick Change II XL mutagenesis to insert a PCR fragment at the
capsid/E3 junction that encodes the first five amino acids of E3
fused in-frame with firefly luciferase (fLuc) followed by the 2A-like
protease of Thosea asigna virus. Stocks of CHIKV-LR, E2 mutant
viruses, and reporter viruses were generated from cDNA clones as
previously described [27]. Briefly, cDNA was linearized and in vitro
transcribed (mMessage mMachine, Ambion) to generate infec-
tious, capped viral RNA genomes. Viral particles were harvested
from supernatant of BHK cells 18–24 h post-electroporation with
these RNAs. For all virus stocks, supernatant was clarified by
centrifugation and single-use aliquots were stored at 280uC.
Genome quantification
Virus stocks (200 mL) were treated with 40 U of RNase ONE
(Promega) for 1 h at 37uC to remove any contaminating RNA that
was not encapsulated in the virion and added to Tri Reagent-LS
(MRC) along with 5 mg of carrier tRNA, before RNA was
extracted per manufacture instructions. Equal total RNA concen-
tration was used for reverse transcription (RT) with a primer
complementary to sequence in the nsP2 gene and tagged with T7
to reduce background (59-CGTAATACGACTCACTATAAG-
TACGTTGACGTGCTCTGACGTT-39). Equal volumes of
cDNA were used for real-time (q) PCR using SYBR green
(Fermentas) to detect nsP2 on the positive strand (nsP2-TC-
fGTGTTAACGTGCTTCAGAGGGT; T7-GCGTAATACGA-
CTCACTATA). A standard curve for viral genome number by
qRT-PCR of RNA in vitro-transcribed from the CHIKV-LR
cDNA clone. qRT-PCR results were analyzed using CFX
Manager software (BioRad).
Molecular modeling
The models of the E1/E2 trimer of the 05-115 CHIKV strain
and mutants, including the E2 N-terminal tail that is missing in the
CHIKV template trimer structure (pdb: 2XFB) [14], were
constructed by using Modeller version 9v8 [30]. The presence of
the N-terminal tail was found to have significant influence on the
electrostatic potential in the areas of interest in the current studies.
Charge of individual atoms and their radius parameters based on
an amber force field [31] were generated by pdb2pqr program
[32]. Electrostatic potential was generated by Adaptive Poisson-
Boltzmann Solver (APBS) package [33]. A linearized Poisson-
Boltzmann equation was applied with dielectric constant 2.0 for
protein and 78.0 for solvent. Electrostatic potential on solvent
accessible surface in the range from -5 kT to 5 kT and solvent
radius 1.4 A was visualized with the PyMol Molecular Graphics
System (PyMol Molecular Graphics System, Schrodinger, LLC).
Morbidity and mortality studies
1 d old CD-1 mice were inoculated subcutaneously in the
ventral thorax, 21 d CD-1 and 8 wk old STAT129 mice were
inoculated subcutaneously in the hind footpad with either 10 ml of
105 genomes or 103 plaque forming units (PFU) of CHIKV viruses
diluted in Optimem (Invitrogen). Mice inoculated with equal
genome equivalents (GE) were inoculated with 105 genomes
(equivalent to,103 PFU of CHIKV-LR). Mice were weighed and
monitored daily for clinical signs of disease and mice showing
severe signs of disease were monitored twice a day. The width and
height of the metatarsal region of the rear footpad of CD-1 and
STAT129 mice were measured daily with a caliper. Changes in
footpad swelling were expressed as fold change in area
(width6height) compared to pre-inoculation area. AST and
percent mortality were calculated. Surviving mice were bled and
challenged with 103 PFU of CHIKV-LR 21 d post primary
infection.
At 48 h post-infection (p.i.), groups of three mice were
euthanized with isofluorane and then exsanguinated by cardiac
puncture to collect blood. The serum was separated from the
blood using Microtainer tubes (Becton-Dixon). Mice were then
perfused with PBS-1% DBS virus diluent (VD). Tissues collected
were homogenized in VD by mechanical disruption. Virus titer
was assessed in supernatants from homogenized tissue by standard
plaque assay on BHK cells and titers were expressed as PFU/g,
mL or draining lymph node (DLN). Serum cytokine concentra-
tions were measured using a mouse cytokine 20-plex kit
(Invitrogen) per manufacture instructions and analyzed using the
BioRad Bioplex 200.
Antibody neutralization assay
Serum was diluted at a final concentration of 1:20 in VD
containing the CHIKV-LR reporter virus expressing fLuc. Serum
and virus were incubated together at room temperature for
30 min before being used to infect a 96-well plate of BHK cells for
1 h at 37uC. Cells were washed twice with VD before culture
media was added and the cells were then incubated for 16 h before
cell lysates were harvested using passive lysis buffer (Promega).
fLuc substrate (Promega) was added and relative light units (RLUs)
were determined by microplate luminometer (Orion).
Infectivity in salt
Virus was diluted in either RPMI1640 (has a basal salt level of
103 mM NaCl) or RPMI1640 containing different concentrations
of NaCl and used to infect MC3T3-E1 cells for 1 h at 37uC before
overlaying with immunodiffusion-grade agarose.
Heparan sulfate dependency assays
Infectivity on pgsA675 and pgsD677 cells. CHOK1
(control cells), pgsA745 (GAG-deficient) and pgsD677 (HS-
dependent) were infected with virus for 1 h at 37uC before
overlaying with immunodiffusion-grade agarose (MP Biomedical).
At 48 h p.i., cells were fixed overnight with 4% paraformaldehyde
(PFA), PFA and overlay were removed, and cells were stained for
CHIKV antigen as previously described [27].
Heparin assays. For the heparin competition assay, virus
was diluted in Optimem (Invitrogen) either containing 200 mg/ml
of heparin (Sigma) or BSA then incubated on ice for 30 min. Then
MC3T3-E1 cells were infected on ice for 30 min to synchronize
infection before overlaying with immunodiffusion-grade agarose
was added for a standard plaque assay. To determine if heparin
could inhibit plaque formation, MC3T3-E1 cells were infected for
1 h at 37uC before overlaying with immunodiffusion-grade
Toward Rational CHIKV Vaccine Design
PLOS Neglected Tropical Diseases | www.plosntds.org 3 February 2014 | Volume 8 | Issue 2 | e2719
agarose containing 200 mg/mL of either heparin or BSA. Plaque
size was measured using a caliper.
Heparinase digestions. MC3T3-E1 cells were washed once
with VD before incubation with various concentrations of Hep I,
II, or III or VD for 1 h at 37uC. Cells were washed twice with VD
and infected for 1 h at 37uC before overlaying with immunodif-
fusion-grade agarose for a standard plaque assay.
Statistical analysis
For the footpad swelling, the area of under the curve was
determined (GraphPad PRISM software) to assess the differences
in swelling during the entire course of infection and then Student’s
t test was used to determine significance. Student’s t test was used
for all other experiments.
Results
In vitro passage of wild-type CHIKV-LR rapidly selects for
positively charged mutations in the E2 glycoprotein
As a proof of concept, we began these studies by passaging
CHIKV on cells from two evolutionarily divergent organisms,
Chinese hamster ovary (CHO) K1 fibroblasts and C6/36 Aedes
albopictus mosquito cells. A population of wild-type strain CHIKV-
LR particles with maximal genome sequence homogeneity was
generated by transfection of in vitro-transcribed, full-length,
infectious viral RNA genomes into BHK-21 fibroblasts. This virus
population was then subjected to a positive selection pressure for
rapid growth on CHOK1 or C6/36 cells by performing ten
sequential passages in triplicate parallel series. Infectious virion
yields in supernatants, harvested after each amplification, declined
slightly on both cell-types in the first two passages (data not shown)
but then gradually increased to surpass passage 1 (P1) yields by
,10 or 1,000-fold on mammalian or mosquito cells, respectively
(Fig. 1). These data gave an initial indication of adaptation to cell
culture within five to 10 passages. Importantly, infectious virion
yields were not significantly enhanced by passage on CHOK1-
derivative pgsA745 cells, deficient in the synthesis of GAG chains,
suggestive that GAG-dependent changes underlay cell culture
adaptation.
The sequence encoding the entire pE2 protein (E3 and E2) was
analyzed from virus populations at P5 and P10 to identify
mutations that might have accumulated during cell culture passage
(Table 1). Each population of RT-PCR products was sequenced to
reveal mutations present in the majority of packaged genomes. In
addition, several individually cloned RT-PCR products from each
P10 population were sequenced to determine whether amino acid
substitutions were occurring alone or together, and to identify
mutations occurring at lower frequency in the population. Passage
on C6/36 mosquito cells selected strongly for an E to K
substitution at E2 position 79, as this variant was the majority
(or consensus) sequence for progeny virus genomes by P5 in three
parallel passage series, and was retained through P10. In two of
five individually cloned pE2 sequences from one passage series, we
also identified a deletion of the codon for negatively charged E2-
166E in mosquito cell-passaged virus populations. This mutation
arose independently of E2-79K, which was found in the other
three sequenced clones for this passage series, and in all sequenced
clones for the two other passage series. Surprisingly, no other
nucleotide mutations were detectable at this depth. Passage on
CHOK1 fibroblasts selected strongly for an S to R substitution at
E2-159 in the majority sequence in each of the three parallel
passage series within five passages, and was retained as the
dominant mutation in two passage series through P10. Interest-
ingly, however, by P10 in the third passage series the dominant
mutation in the population, and in four of six individual clones,
was the E2-79 E to K substitution also selected on C6/36 cells.
Three additional pE2 mutations were revealed in individual virion
sequences. An E2-55 G to R substitution occurred at two out of
five frequency in the second passage series on CHOK1 cells, while
the combination of E2-99 H to Y/E2-168 E to K was present in
two out of six of the population of the third passage series. After
serial passage on GAG-deficient CHO cells, a dominant E2-264 V
to A substitution was detected in one of three passage series at P5
and two of three at P10.
E2 glycoprotein electrostatic potential is altered by the
cell culture-adaptive mutations
In total, seven amino acid changes were identified in the E2
proteins of the cell culture-passaged virus populations, four of
which substituted a neutrally, or negatively, charged residue with a
positively charged one (G to R at E2-55; E to K at E2-79; S to R at
E2-159 and E to K at E2-168), while a fifth deleted a negatively
charged amino acid (E2-D166E). Neither the V to A substitution at
E2-264 nor the H to Y substitution at E2-99 would be anticipated
to alter the net charge.
Based upon the X-ray crystallographic E1/E2 heterotrimeric
structure of the CHIKV clinical isolate 05-115 [14,34], we
generated a 3D structural model of the trimeric envelope
Figure 1. Cell culture passage of CHIKV-LR. CHIKV-LR virus stock was serially passaged 10 times in triplicate parallel series on: A) CHOK1; B) C6/
36; or C) pgsA745 cells. After each amplification, the quantity of infectious virions was titered on BHK-21 fibroblasts by standard plaque assay. The
fold-increase in titer at passage (P) 5 and P10 were normalized to the titer at P1. Each bar represents one individual passage series.
doi:10.1371/journal.pntd.0002719.g001
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glycoprotein heterodimer (Fig. 2A) and used Adaptive Poisson-
Boltzmann Solver (APBS; [33]) to determine the electrostatic
potentials for the trimer-heterodimers of the wild-type CHIKV-
LR strain and the identified mutations (Fig. 2B–D). The cell
culture passage-selected E2 mutations mapped to two regions
previously defined by Voss et al. [14]. Residues E2-55 and E2-79
mapped to the ‘‘wing’’ portion of Domain A in the region of
insertion strands i3, i5 and i6 into Ig-like domains (Fig. 2C). The
E2-82R mutation selected during 18 serial passages of the 15561
wild-type CHIKV strain on MRC-5 fibroblasts to produce the
181/25 CHIKV LAV candidate [35], and previously shown to
attenuate both 15661 and CHIKV-LR [28], also mapped within
this region. When viewed from above the three-fold axis of
symmetry (Fig. 2B), the E2-55 residue resides in a cleft, overhung
by other portions of Domain A, but facing outward from the spike
interior adjacent to the b ribbon connector, whereas the E2-79
and E2-82 residues lie toward the apical surface of the protein,
facing the solvent-exposed interior of the E1/E2 heterotrimer,
with E2-79 more exposed than E2-82.
The E2-159R, E2-D166E and E2-168K mutations mapped to
the acid-sensitive region in arch 1 of the b ribbon connector
between Domains A and B (Fig. 2D). Interestingly, an E to K
substitution at E2-166 was previously selected during passage of
CHIKV-06.049 on human epithelial carcinoma HeLa cells [36].
The E2-159, E2-166 and E2-168 residues lie within the b ribbon
connector facing outward from the heterotrimeric spike interior
essentially on the opposite side of the E1/E2 heterodimer from E2-
79 and E2-82 residues. E2-166 and E2-168 residues are close to
areas of contact between the b connector and E1, although residue
E2-166 is located more towards the heterotrimer exterior than E2-
168 which is deeper within an invagination of the spike between
the b connector and E1. The E2-159 residue lies higher and more
towards the cleft in Domain A, where E2-55 is located.
For ease of viewing, regions affected by the changes in
electrostatic potential created by each mutation are shown
magnified on only one of the E2 molecules in the heterotrimer
(Fig. 2E & F). Those amino acid mutations that were predicted to
increase net positive charge also produced localized increases in the
computer-predicted positive electrostatic potential on the surface of
the E2 protein. In contrast, the E2-D166E deletion mutation
appeared to affect a broader area and, at the resolution of the
model, alter contact regions between the b connector and E1. The
prominent exposure of the positive-charge shift conferred by the
highly attenuating E2-79K mutation in comparison with the
similarly located E2-55R and E2-82R is particularly apparent in
the top view of the spike three-fold axis of symmetry (Figs. 2H–J).
Positively charged amino acid substitutions in E2 result in
a range of HS dependencies
Each amino acid substitution or deletion discussed above,
including E2-82R and E2-166K, was introduced separately into
the CHIKV-LR cDNA clone. Stocks of CHIKV-LR and the E2
mutant viruses were generated by transfection of in vitro-transcribed,
capped genomes, and not passaged further. Reasoning that the
positive electrostatic potential increases in E2 would result in a
dependency upon cell surface HS for infectivity, we compared
Table 1. Mutations identified in the E2 glycoprotein at passage 5 and 10 after cell culture adaptation of CHIKV-LR.
Virus E2 amino acid position
55 79 82 99 159 166 168 264
WT-LR G E G H S E E V
CHOK1 5.1 G E G H R E E V
CHOK1 5.2 G E G H R E E V
CHOK1 5.3 G E G H R E E V
CHOK1 10.1 G E G H R E E V
CHOK1 10.2 G E G H R E E V
CHOK1 10.2a R E G H S E E V
CHOK1 10.3 G K G H S E E V
CHOK1 10.3a G E G Y S E K V
C6/36 5.1 G K G H S E E V
C6/36 5.2 G K G H S E E V
C6/36 5.3 G K G H S E E V
C6/36 10.1 G K G H S E E V
C6/36 10.2 G K G H S E E V
C6/36 10.3 G K G H S E E V
C6/36 10.3a G E G H S - E V
pgsA745 5.1 G E G H S E E V
pgsA745 5.2 G E G H S E E A
pgsA745 5.3 G E G H S E E V
pgsA745 10.1 G E G H S E E V
pgsA745 10.2 G E G H S E E A
pgsA745 10.3 G E G H S E E A
Suffix ‘a’ indicates mutations identified only in individual viruses but not in the majority population.
doi:10.1371/journal.pntd.0002719.t001
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particle infectivity on CHOK1 cells versus derivatives that lack the
ability to synthesize either all GAG chains (pgsA745) or just HS
(pgsD677; [37]). Like other Old World alphaviruses, the infectivity
of wild-type CHIKV-LR did not depend upon the presence of these
sulfated glycans (Supplemental Fig. S1; [27,38]). In contrast, the
infectivities of LR-55R, LR-79K, LR-82R, LR-159R, LR-166K,
LR-D166E and LR-168K for CHO cells all exhibited significant
dependence upon GAGs, and this phenotype was almost completely
conferred by the absence of HS alone. Neither E2-99Y, nor E2-
264A mutation, exhibited significant dependence upon GAGs for
infectivity (data not shown). In our experience the usefulness of the
pgsD677 and pgsA745 CHO cells is limited to determining whether
or not viral infectivity is affected by the absence of HS or GAGs but
does not accurately determine relative degrees of dependency.
However, these data indicate that predicted increase in exposed
positive charge on E2 in the trimer-heterodimeric spike correlates
with a significant dependence upon HS for infection of CHO cells.
Most of the mutations increased per-particle infectivity, with the
notable exceptions of E2-D166E and E2-159R (data not shown),
which reduced infectivity unless HS was present, indicating that the
latter mutations may compromise attachment/entry via another
receptor(s) pathway used by CHIKV-LR.
Positively charged amino acid substitutions in E2 confer
a range of virulence phenotypes in vivo
Focusing upon those mutations that increase electrostatic
potential on the E2 surface positive charge compared to wild-
type CHIKV-LR (Fig. 2), and conferred the ability to bind HS
(Supplemental Fig. S1), the virulence of each mutant relative to
Figure 2. Effects of positively charged amino acid substitutions in the CHIKV E2 glycoprotein on electrostatic potential in the E1/E2
trimer-heterodimeric spike. The trimeric CHIKV-LR E1/E2 heterodimer was modeled and APBS was used to determine the electrostatic potential of
the CHIKV-LR E2 protein, the location of mutated residues and predicted changes to the electrostatic potential conferred by these mutations. (A) Top
view of the CHIKV-LR trimer-heterodimer with E1 shown in gray, E2 domain A in cyan, domain B in green, and domain C in brown. (B–D) The
electrostatic potential of the CHIKV-LR trimer-heterodimer where blue indicates positive charge, white indicates neutral charge and red indicates
negative charge. B) top view; C) side view I; and D) side view II. (E & F) For ease of viewing, the region of the E2 molecule altered by each mutation is
magnified showing only one of the E2 molecules in the trimer-heterodimer. E) Magnification from side view I of the ‘‘wing’’ portion of domain A that
contains the E2-55R, E2-79K and E2-82R mutations; F) Magnification of side view II of the acid sensitive region in arch 1 between domains A and B
that contains the E2-159R, E2-D166E/166K and E2-168K mutations. G–J) The top view of the electrostatic potential of trimetric heterodimer for the E2
mutations in the ‘‘wing’’ portion of domain A: G) CHIKV-LR, H) E2-55R, I) E2-79K and J) E2-82R.
doi:10.1371/journal.pntd.0002719.g002
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wild-type CHIKV-LR was assessed in a murine model of MSD
with edema/inflammation, by measuring hind-limb swelling
across the metatarsal region after subcutaneous inoculation of
virus into the footpad, as described previously [27,39,40].
Two waves of limb swelling were consistently observed in mice
infected with CHIKV-LR, the first peaking 1–2 d p.i., and the
second 6–7 d p.i., with complete resolution by 12–14 d p.i. (Fig. 3A).
Varying degrees and patterns of attenuation compared to the wild-
type virus were observed for the mutant viruses, which we grouped
into three categories for clarity. In the first category (purple), little or
no attenuation was observed for LR-D166E infection (Fig. 3B)
compared to wild-type CHIKV-LR, although the onset of clinical
signs was delayed by ,24 h and the duration of disease was longer
for some animals. In the second category (blue), partial attenuation
was observed for several virus mutants (Fig. 3C–E). LR-168K
(Fig. 3C) was ,24 h delayed and attenuated at 1–2 d p.i. but
produced wild-type levels of swelling in some cases in the second
phase. Interestingly, some animals infected with LR-168K also
exhibited a more prolonged swelling than we observed for the wild-
type virus infection. LR-55R (Fig. 3D) and LR-159R (Fig. 3E) were
not delayed but demonstrated significantly reduced swelling
compared with CHIKV-LR in both waves. In the third category
(green), three virus mutants were highly attenuated, causing little or
no hind-limb swelling (Fig. 3F–H). LR-166K (Fig. 3F) caused a
transient, mild swelling only in the second wave, whereas no
evidence of swelling was detectable for LR-79K (Fig. 3G) or LR-
82R (Fig. 3H). This categorization and color scheme is used for
subsequent figures to demonstrate prominent associations of
genotype and phenotype.
A number of chemokines and cytokines have been associated
with the acute phase of disease in humans, including MIG
(CXCL9), MCP-1 (CCL2) and IP-10 (CXCL10) [41–45].
Furthermore, in a murine model similar to the one used here,
MCP-1 has been shown to play an important role in pathogenesis
of CHIKV-induced MSD [39,41]. Interestingly, comparison of
inflammatory responses to CHIKV-LR and the E2 mutant viruses
revealed that higher induction of two cytokines (IL-12 p35/p40
and IL-5) and three chemokines (MCP-1, MIG and IP-10)
correlated well with the severity of MSD (Fig. 4). On the other
hand, IL-1a, IFN-c and IL-2 were significantly induced in all
virus-infected animals at 48 h p.i. versus mock-infected counterparts
but no association between disease severity and these cytokine
levels was observed (Fig. 4 and Supplemental Table S1). No
significant elevation of other measured cytokines was observed
over mock-infected animals for any of the viruses during this acute
phase of infection (Supplemental Table S1). These data not only
indicate that the levels of certain inflammatory molecules provide
early biomarkers of MSD severity or attenuation in mice, but
further validate the murine model of human infection.
Positive charge E2 mutations tend to increase specific
infectivity of virus particles and infectivity was
dependent on ionic interactions in vitro
In an effort to identify particular in vitro phenotypes that could
be used to identify promising mutations for a LAV, we compared
multiple characteristics of the dependence of infectivity of each
mutant upon HS. By calculating plaques per GE (specific
infectivity), we estimated that under plaque assay conditions,
,1% of wild-type CHIKV-LR virus particles initiated infection on
BHK-21 fibroblasts, 0.1% on Vero cells, 0.05% on CHOK1 cells
and 0.01% on MC3T3-E1 osteoblasts (Fig. 5A). These suscepti-
bility differences may be due to reduced attachment, entry and/or
to subsequent steps in propagation. The LR-D166E mutant
exhibited minimal changes in specific infectivity on the four cell-
types compared to wild-type CHIKV-LR. Otherwise, with a few
exceptions (E2-55R on Vero and MC3T3-E1, and E2-159R on
CHOK1 and MC3T3-E1), the cell culture passage-derived E2
mutations tended to increase the infectivity of CHIKV particles by
up to 70-fold (Fig. 5B) and thus provided an advantage to virions
in culture conditions. However, these data also indicated that the
virus-host receptor interactions differ between cell-types, as the
hierarchies of cell susceptibility and virion infectivity were not
consistently maintained.
To further explore in vitro phenotypes we focused upon the
MC3T3-E1 osteoblasts as a cell-type with relevance to CHIKV-
Figure 3. Musculoskeletal disease following subcutaneous infection of CD-1 mice with E2 mutant viruses. 21 d old CD-1 mice were
infected subcutaneously in the left rear footpad with 105 GE (normalized to 103 PFU of CHIKV-LR) and the metatarsal region (height and width) was
measured daily; fold-change over day 0 was calculated based upon pre-infection footpad area. Viruses are color-coded based on disease phenotype:
(A–B) hind-limb swelling with little or no attenuation (purple; (A) CHIKV-LR and (B) LR- D166E), (C–E) partial attenuation (blue; (C) LR-168K, (D) LR-55R
and (E) LR-159R) and (F–H) highly attenuated with little or no hind-limb swelling (green; (F) LR-166K, (G) LR-82R and (H) LR-79K) compared to CHIKV-
LR. Individual mice are graphed with the intensity of shading indicating the proportion of mice with overlapping levels of hind-limb swelling.
*p,0.001 compared to CHIKV-LR.
doi:10.1371/journal.pntd.0002719.g003
Toward Rational CHIKV Vaccine Design
PLOS Neglected Tropical Diseases | www.plosntds.org 7 February 2014 | Volume 8 | Issue 2 | e2719
induced MSD in vivo [46] and known to secrete extracellular
matrix components including HSPGs [47]. Virus inocula were
prepared in media with a range of salt concentrations to disrupt
potential ionic interactions between the virus particles and cell-
surfaces during the infection period. As expected from our prior
studies, the infectivities of wild-type SINV (SINV-TR339) and
CHIKV-LR particles exhibited no significant dependence upon
ionic interaction, whereas an E2-70K mutation in SINV-TR339
(SINV-K70) makes this virus highly sensitive to ionic interactions
[17,21,27]. Interestingly, although the electrostatic model of the
E2 protein predicted that the deletion of residue E2-166E would
increase net-positive charge, the infectivity of LR-D166E virus for
MC3T3-E1 osteoblasts was insensitive to even the highest salt
concentration (350 mM; Fig. 5C), and indistinguishable from wild-
type CHIKV-LR by this assay. The infectivity of the other viruses
with positively charged E2 amino acid mutations was significantly
disrupted at 200–250 mM salt concentration (Fig. 5C), indicating
that the vast majority of virions now relied upon an ionic
interaction for infectivity.
Increased infectivity tends to be conferred by ionic
interactions, sensitive to blocking by heparin
When we examined the ability of a high concentration of
soluble heparin (200 mg/mL) to block infection of MC3T3-E1
osteoblasts (Fig. 6A), we were surprised to discover that only LR-
79K, LR-82R and LR-166K were effectively competed versus
BSA-treated controls and this treatment reduced infectivity by
.90%. However, heparin is a uniformly highly sulfated GAG,
lacking the diversity of HS chain charge distributions and
therefore does not necessarily block all HS-ligand interactions. It
should also be noted that, because the soluble heparin treatment
unexpectedly increased the infectivity of wild-type CHIKV-LR on
MC3T3-E1 cells by ,15%, all of the mutations except for E2-
D166E significantly increased sensitivity to heparin blocking even
if only by a small fraction. Compared to previous observations for
other alphaviruses that ionic interactions were almost completely
HS-mediated and competed by soluble heparin [17,19,20,29,48],
these findings suggest a more complicated interaction for these
CHIKV mutants.
While performing the above experiments, it was noted that
plaque sizes on MC3T3-E1 osteoblasts were highly variable
between mutants (Fig. 6B). When quantified and compared with
CHIKV-LR (Fig. 6C), it was revealed that the plaques formed by
LR-166K, LR-82R and LR-79K were extremely small, LR-168K
plaques were of intermediate size, while the plaque sizes of LR-
D166E, LR-55R and LR-159R did not differ significantly from
wild-type virus. The heparin blocking assay measures only the
ability of the virus to initiate infection in the presence of varying
amounts of heparin. As an extension to this assay, we determined
whether or not the addition of heparin to the overlay impacted
virus plaque size phenotypes as a more sensitive measurement of
HS-dependence. As expected the plaque size of the wild-type virus
was not affected (Fig. 6D). The three viruses exhibiting the smallest
plaque size were also unaffected by added heparin, presumably
because cell-surface or extracellular matrix HS already inhibits the
spread of these highly sensitive mutants. However, heparin
reduced the plaque sizes of LR-55R and LR-168K to a size
comparable with LR-79K, LR-82R and LR-166K, and reduced
Figure 4. Cytokine induction following subcutaneous inoculation of CHIKV E2 mutant viruses. 21 d old CD-1 mice were infected
subcutaneously in the left rear footpad with 105 GE. At 48 h p.i. sera were collected and analyzed for cytokine/chemokine induction using a 20-plex
luminex bead kit. A) IP-10; B) MCP-1; C) MIG; D) IL-12; E) IL-5; F) IL-1a. Viruses are color-coded based on MSD severity: little or no attenuation (purple),
partial attenuation (blue) or highly attenuated (green) compared to CHIKV-LR. Error bars represent standard deviation. *p,0.05 and **p,0.01
compared to CHIKV-LR.
doi:10.1371/journal.pntd.0002719.g004
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the plaque size of LR-159R and LR-D166E, significantly. The
reduced plaque size of LR-D166E under heparin overlay along
with the reduced infectivity on HS-deficient CHO cells (Supple-
mental Fig. S1) suggested that this virus has a slight dependence on
HS depending upon culture conditions, which fit with the
prediction of an alteration of the positive electrostatic potential.
Increased infectivity conferred by positively charged E2
mutations tends to be disrupted by HS digestion from
cell surfaces
We examined the infectivity of each virus for MC3T3-E1 cells
digested with microbial heparinases, (Hep) I, II and III, which
digest cell-surface HS chains (recently reviewed in [49]). Hep II
acts with little specificity, cleaving both HS chains and heparin
regardless of sulfation. In contrast, Hep I cleaves primarily heparin
and highly sulfated HS regions, while Hep III primarily cleaves
less-sulfated regions of HS chains. Thus, the HS structures
remaining on the cell surface after digestion differ between
heparinases. Successful digestion of HS was confirmed by the
greatly reduced infectivity of SINV-K70. As expected, viruses with
little infectivity dependence upon HS (SINV-TR339, CHIKV-LR
and LR-D166E) were unaffected by the digestion of HS chains
with Hep I, II or III, even when high concentrations of enzyme
were used (Fig. 7A–C). With the exception of LR-55R, heparin
blocking (Fig. 6A) correlated with .90% reduction in infectivity
on MC3T3-E1 cells digested with Hep II. However, the
infectivities of these viruses were only reduced ,50% by digestion
with Hep I or III suggesting that they were able to utilize residual
chains for infection regardless of their sulfation level, unlike SINV-
K70. The infectivity of LR-55R was reproducibly reduced by only
,50% following digestion with Hep I, II or III. Overall, LR-79K
infectivity appeared to be the most sensitive to the digestion of HS,
followed by LR-166K.
Attenuation of E2 mutants in vivo correlates with
decreased spread from site of inoculation
To better understand the reasons for attenuation of the HS-
binding E2 mutants in vivo, especially LR-79K and LR-82R, we
measured viral load in various tissues at 48 h p.i. (Fig. 8). This
time-point was chosen to represent the first peak of swelling, and
the previously observed peak of CHIKV-LR replication in this
model [27].
Site of inoculation and musculoskeletal tissues. With the
exception of LR-55R, viral titers at the inoculation site were
Figure 5. Positive charge CHIKV E2 mutations increase specific infectivity and infectivity is dependent on ionic interactions. Specific
infectivity (GE/PFU) of A) CHIKV-LR WT; and B) the mutants CHIKV E2 mutants were evaluated on different cell types. For the CHIKV E2 mutants, fold-
change in specific infectivity was normalized to CHIKV-LR. C) CHIKV E2 mutants were evaluated for dependency on ionic interaction for infectivity by
interacting virus in either RPMI1640 (basal salt concentration of 103 mM NaCl) or RPMI1640 with increasing salt concentration and MC3T3-E1 cells
were then infected for a standard plaque assay. Percent infectivity was normalized to 103 mM NaCl, which was set to 100%. Viruses are color-coded
based on control groups (orange) or MSD severity: little or no attenuation (purple), partial attenuation (blue) or highly attenuated (green) compared
to CHIKV-LR. Error bars represent standard deviation. *p,0.01 and **p,0.001 compared to CHIKV-LR (B) or 103 mM NaCl (C).
doi:10.1371/journal.pntd.0002719.g005
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similar to or higher than those of wild-type virus suggesting that
the different E2 mutants were all capable of initiating replication
in the skin (Fig. 8A). Viral loads for the attenuated E2 mutants
were generally lower in MSTs than wild-type CHIKV-LR (Fig. 8B
& C), whereas the LR-D166E mutant titers were comparable to
wild-type, and LR-159R infection produced similar viral load in
the knee joint as CHIKV-LR in keeping with the observed hind
limb swelling. However, it was surprising to discover that LR-82R
replicated to similar titer in the quadriceps muscle as the wild-type
virus since this mutant caused no detectable MSD.
DLN, serum viremia and spleen. All of the attenuated
viruses (groups 2 and 3) exhibited a highly significant inability to
amplify within the DLN (Fig. 8D), suggesting a reduced or delayed
spread either within the lymphatic vessels to the DLN or within
the organ itself. With the exception of LR-168K, the viremic titers
were also significantly reduced or undetectable in the cases of LR-
166K, LR-82R and LR-79K (Fig. 8E). Notably, there was no
detectable presence of the three most attenuated viruses, LR-79K,
LR-82R, and LR-166K, in the spleen either likely due to the
absence of viremic spread by this time p.i. (Fig. 8F). These data
suggest that the attenuated E2 mutants are impaired to differing
degrees in their ability to spread from the site of inoculation with a
high degree of association with MSD severity. It is interesting,
however, that viral loads in lymphoid tissues and serum viremia
appear to correlate better with MSD and cytokine/chemokine
levels than MST titers.
Attenuation of E2 mutants in an immunocompromised
mouse models
Based upon the studies above, we proposed that two of the
mutant viruses were sufficiently attenuated for inclusion in LAV
vaccine formulations: LR-82R and LR-79K. To stringently
determine the degree and stability of their attenuated phenotypes,
we infected more susceptible animals. We have previously shown
that mice deficient in STAT1-dependent type I IFN signaling
pathways had exacerbated MSD, whereas CHIKV-181/25
remained partially attenuated in these animals [27]. STAT1-
deficient mice infected with LR-82R exhibited exacerbated hind
limb swelling compared to 129/Sv control animals, similar to that
caused by wild-type CHIKV-LR (Supplemental Fig. S2). Howev-
er, LR-79K infection of the STAT1-deficient mice caused only
mild MSD compared to CHIKV-LR and LR-82R, from which we
infer that LR-79K is substantially more attenuated for ability to
cause MSD than LR-82R or even the 181/25 LAV. Both LR-82R
Figure 6. Soluble heparin can block infectivity and alter plaque size of several of the positive charge CHIKV E2 mutants on MC3T3-
E1 osteoblasts. A) Soluble heparin was used to block infectivity of the virus by competing with the ability of the virus to attach to cells. Virus was
incubated with 200 mg of either soluble heparin or BSA, infection was synchronized and overlay was added for a standard plaque assay. Percent
heparin blocking was normalized to BSA control. B & C) Standard plaque assay on MC3T3-E1 was used to determine plaque size of the different CHIKV
viruses. C) Plaque sizes were quantified by measuring the size of the plaques using a caliper. D) Virus was titered using a standard plaque assay on
MC3T3-E1 cells in the presence or absence of 200 mg/mL of soluble heparin in the overlay. Plaque sizes were quantified by measuring the size of the
plaques using a caliper. Viruses are color-coded based on control groups (orange) or MSD severity: little or no attenuation (purple), partial attenuation
(blue), or highly attenuated (green) compared to CHIKV-LR. Error bars represent standard deviation. *p,0.001 compared to CHIKV-LR (B) or 103 mM
NaCl (C).
doi:10.1371/journal.pntd.0002719.g006
Toward Rational CHIKV Vaccine Design
PLOS Neglected Tropical Diseases | www.plosntds.org 10 February 2014 | Volume 8 | Issue 2 | e2719
Figure 7. HS-dependent infectivity of the CHIKV E2 mutants by removal of HS on MC3T3-E1 cells. CHIKV E2 mutants were evaluated for
dependency on HS for infectivity on MC3T3-E1 cells by digestion of HS with different heparinases (Hep). MC3T3-E1 cell surfaces were mock-treated, or
digested with various concentrations of A) Hep I; B) Hep II; or C) Hep III and then infected with virus for a standard plaque assay on MC3T3-E1 cells.
Percent infection was normalized to mock treatment which was set to 100%. Viruses are color-coded based on control groups (orange) or MSD
severity: little or no attenuation (purple), partial attenuation (blue), highly attenuated (green) compared to CHIKV-LR. Error bars represent standard
deviation. For all heparinases at all concentrations, there was no significant difference in infectivity for SINV-TR339, CHIKV-LR and LR-D166E compared
Toward Rational CHIKV Vaccine Design
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and LR-79K infections were lethal to the STAT1-deficient mice,
however, supporting our prior contention that MSD and fatality
are not closely linked.
LR-79K and LR-82R elicit protective immunity and
neutralizing antibodies
Finally, we immunized CD-1 mice with LR-82R or LR-79K,
and challenged with CHIKV-LR three weeks p.i., to determine
whether or not these attenuated E2 mutants could efficiently elicit
a protective adaptive immune response. All of the immunized mice
were completely protected from development of MSD upon
CHIKV-LR challenge, whereas mock-immunized mice developed
mild MSD (Fig. 9A). Only the second wave of swelling was
observed in these control animals most likely due to the ongoing
age-dependent attenuation of CHIK-LR-induced MSD in this
model. Protection from disease was coincident with the presence of
neutralizing antibodies prior to challenge (Fig. 9B) and, although
we have not shown directly that this confers the immunity,
antibody responses have been shown to protect [50,51]. Interest-
ingly, all of the E2 mutants elicited levels of neutralizing antibody
not dissimilar to the wild-type infection by 21 d p.i. (Fig. 9B and
data not shown), despite there being highly significant differences
in dissemination, replication and disease.
Discussion
The gold standards for a successful LAV against mosquito-
borne virus infection are the 17D strains of yellow fever virus
(YFV), currently used for routine immunization where YFV is
endemic and in regional mass vaccination campaigns at the first
sign of an outbreak [52]. The 17D vaccines immunize 99% of
vaccinees with only one inoculum dose, provide immune memory
for decades, and very rarely cause vaccine-associated adverse
events. The original 17D virus was fortuitously selected by
extensive blind cell culture-passage in the 1930’s [53]. Although,
the molecular mechanisms underlying the consistent immunoge-
nicity and stable attenuation of 17D are largely unknown and
cannot yet be intentionally duplicated for viruses or even for YFV,
increased HS interaction has been identified as significantly
contributing to the attenuation of 17D [54]. Alphavirus LAV
candidates have been generated for VEEV (TC83; [55]) and
CHIKV (181/25; [9]) by serial passage in cell culture but both
have encountered problems during clinical trial for reasons of
inadequate immunogenicity in some vaccinees and residual
virulence in others. Yet, both of these vaccines are attenuated, at
least in part due to more efficient interaction with HS than their
wild-type counterparts [27,48]. Attaining the ideal balance
between attenuation of disease and immunogenicity is extremely
challenging, and to do so by design will require knowledge of virus
biology and the optimization of rational attenuation strategies that
can be combined to produce a safe and effective vaccine. Thus,
one characteristic of most, if not all, arbovirus LAV is increased
HS interaction over the wild-type virus, yet these mutations have
previously been selected at random as a component of extensive
blind passages without knowledge of their contribution to
attenuation of the vaccine.
Our current studies represent the first attempt to evaluate
systematically selected mutations that confer interaction with HS
and attenuate CHIKV in vivo. We began by assuming that a
rational method for identification of a panel of E2 glycoprotein
mutants highly enriched in HS binding mutations would be serial
passage of CHIKV virus on two evolutionarily divergent cell types.
Within an organism, HS biosynthesis is primarily regulated by
domain distribution and degree of sulfation (i.e., the distribution of
to the no Hep control. For all of the CHIKV E2 mutants, with the exception of LR-159R at 0.5 U/mL of Hep III, had a significant decrease in infectivity
compared to the mock-treated control (p,0.01).
doi:10.1371/journal.pntd.0002719.g007
Figure 8. Viral load following subcutaneous inoculation of CHIKV E2 mutants. 21 d old CD-1 mice were infected subcutaneously in the left
rear footpad with 105 GE. At 48 h p.i., A) footpad; B) quadriceps muscle; C) knee joint; D) popliteal lymph node (LN); E) serum; and F) spleen were
harvested and analyzed for viral load by standard plaque assay. The limit of detection (LD) per g, mL, or LN is indicated. Viruses are color-coded based
on MSD severity: little or no attenuation (purple), partial attenuation (blue) or highly attenuated (green) compared to CHIKV-LR. Error bars represent
standard deviation. *p,0.05, **p,0.01 and ***p,0.001 compared to CHIKV-LR.
doi:10.1371/journal.pntd.0002719.g008
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N-substituents and the levels of 2-O- and 6-O-sulfation) resulting in
different composition of HS species from different cellular or tissue
sources [56,57]. Furthermore, invertebrate HS has a number of
unique properties, including unusually low O-sulfation, yielding
different domain structures from vertebrate HS [58,59]. This
diversity most likely results in the duality of both non-specific ionic
interactions occurring between HS and positively charged ligands
versus highly specific interactions of particular ligands with certain
HS species [60–63]. Specificity for particular HS structures has
been documented for several virus-HS interactions [38,64].
Therefore, it was possible that mutations affecting the charge
balance of E2 selected on different cell types might exhibit
different types of HS interaction. While the particular contribution
of HS binding to alphavirus infection is not fully characterized
beyond increases in virus association with cells [17,21,24], it is
possible that structural differences in HS chains, their attachment
to core proteins or their associations with other cell surface factors
may be involved in the selective advantage provided by a
particular virus mutation in vitro.
Comparing CHO and C6/36 cell passage series, we obtained
one common mutation altering charge (E2-79 E-K), three CHO-
only mutations (E255 G-R, E2-159 S-R and E2-168 E-K) and one
C6/36-only mutation (deletion of E2-166E). Neither the V to A
substitution at E2-264, nor the H to Y substitution at E2-99, would
be anticipated to have considerable impact upon electrostatic
potential; therefore, these were not considered. Interestingly, the
E2-159R selected in these studies was previously selected during
passage of CHIKV on Vero primate kidney fibroblast cells [65],
the E2-166K was selected on HeLa human adenocarcinoma cells
[36], and the E2-82R in the vaccine strain was selected on MRC-5
human fetal fibroblast cells [9], although none of these studies
deliberately selected for increased infectivity or HS interaction.
Therefore, common mutations can be selected between evolu-
tionarily divergent hosts (E2-79 E-K in hamster and mosquito, and
E2-159 S-R in monkey and mouse) while it is possible that others
are unique to particular cells or species. While not considered in
our studies, it is possible that the number of different mutations
selected would be increased by using cells from different tissue
types reflecting the diversity of tissue specific HS structure
described above.
To determine whether or not the mutations identified were
unique to cell culture-adapted virus populations, we examined
these positions in an alignment of 200 pE2 sequences available in
GenBank and believed to be from isolates minimally or
unpassaged before sequencing (Gardner et al., unpublished
observations). Only two of the mutations selected in our study
were present in any of these isolates: four isolates had E2-55R
(ADV31296, AEE60792, AEE60797 and BAH97931) and 10
isolates had the E2-264A (AEX25348, AEX25344, AEX25346,
AEE60795, AEE60793, AEE60796, AEE60794, AEE60792,
CCA61129 and CCA61128). Whether or not these residues are
present in naturally circulating viruses or represent cell culture
adaptive mutations in the minimally passaged strains remains to be
determined.
With the exception of LR-D166E, all of the E2 mutants were
attenuated for the ability to cause MSD in mice. Although all of
the viruses were clearly able to replicate at the site of inoculation in
the footpad, in general their replication in MST was reduced. The
virus mutants fell into three groups of disease severity with LR-
D166E disease indistinguishable from CHIKV-LR; LR-168K,
LR-55R and LR-159R eliciting a biphasic MSD similar to
CHIKV-LR but with reduced disease; and LR-166K, LR-82R
and LR-79K eliciting either a minor monophasic MSD (LR-
166K) or no detectable MSD (LR-82R and LR-79K). As
Figure 9. Protective immunity and neutralizing antibody elicited by LR-82R and LR-79K. 21 d old CD-1 mice were infected with 105 GE of
CHIKV-LR WT, LR-82R, or LR-79K subcutaneously in the rear footpad. At 21 d p.i., mice were bled and challenged with 103 PFU of CHIKV-LR. A) Hind-
limb swelling post-challenge was determined by measuring the metatarsal region (height and width) daily and fold change was calculated based on
pre-challenge footpad area. The legend indicates the virus used for the primary infection. Individual mice are graphed with the intensity of shading
indicating the proportion of mice with overlapping levels of hind-limb swelling. B) Neutralizing antibody levels were determined by interacting a
CHIKV-LR luciferase-expressing virus with sera and then infecting cells overnight. Lysates were then harvested and analyzed for luciferase signal.
Levels of neutralizing antibody were determined as fold reduction in luciferase signal compared to mock sera. Error bars represent standard
deviation.
doi:10.1371/journal.pntd.0002719.g009
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suggested by studies with other alphaviruses [17,20,48], the
dependence upon HS for infectivity prevents efficient spread of
CHIKV in vivo. In the current studies, this led to decreased levels
of inflammatory chemokines such as MCP-1, MIG and IP-10 that
are associated with CHIKV-induced disease. Further, the most
attenuated viruses elicited the lowest levels of these factors. It was
not surprising that the levels of IP-10 and MCP-1 correlated with
attenuation, as these cytokines are chemoattractants for mono-
cytes/macrophages which have been shown to be important for
disease mice [39,41] and humans, especially during the acute
phase of disease [42–44,66], and can be associated with higher
CHIKV loads [44]. MIG and IL-12 are involved in T cell
recruitment and differentiation respectively and have been shown
in some human cohorts to be elevated during infection [42–45,66],
and CD4+ T cells have been shown to contribute to hind limb
swelling in mice [67]. IL-1a, IFN-c and IL-2 were increased in the
serum of mutant viruses similarly to wild-type CHIKV-LR and
several of these cytokines were also shown to be upregulated
during human infections [41,43–45,66]. It remains to be
determined if elevation of these cytokines is associated with the
attenuated phenotype and/or the induction of the protective
immune response. Taken together, the cytokine profiles in mice
correlated with virulence and for many of the cytokines are similar
to profiles in humans following CHIKV-LR infection.
We attempted to associate in vitro measurements of HS infection
dependence with virulence, examining virus specific infectivity,
infection efficiency in the absence of HS or all GAGs, plaque size,
resistance of infectivity to competition with increasing salt
concentrations, sensitivity to competition with heparin, and
infection sensitivity to digestion of cell surfaces with heparinases.
Each of these assays has previously been used to compare HS
infectivity dependence of alphaviruses (e.g., [17,19,21,22,48,68]).
All viruses attenuated in comparison with CHIKV-LR did exhibit
increased specific infectivity on at least one of the four cell types
tested and this was associated with similar infectivity diminution in
cells genetically deficient in GAG synthesis. LR-D166E depen-
dence on HS was significantly less than the other mutants but
much greater than CHIKV-LR indicating that at least partial
dependence upon HS for infectivity is not invariably associated
with attenuation. Interestingly, in contrast with the SINV-K70
mutant whose infectivity appeared to depend solely upon HS
among GAGs, all CHIKV mutants exhibited a minor dependence
of infectivity upon GAGs other than HS evidenced by slightly
increased infectivity on HS-deficient pgsD-677 cells versus GAG-
deficient pgsA745 cells. This suggests the possibility of differences
in attachment/entry mechanisms of SINV versus CHIKV.
Disruption of infection with salt did not distinguish between
attenuated mutants with each exhibiting moderate decrease at
200 mM and ,90% decrease in infectivity at 250 mM and above.
Interestingly, LR-D166E, although sensitive to genetic deficiency
in HS and all GAGs, was insensitive to all salt concentrations used,
similar to CHIKV-LR. Furthermore, digestion of HS chains with
Hep I, II or III did not distinguish the three groups of attenuation
phenotypes. Likely reflecting the different substrate specificities of
the three enzymes, differential sensitivity to the three heparinases
can distinguish between virulence phenotypes with other alpha-
viruses with genetic differences in HS binding domains [17,29]. In
these studies, CHIKV-LR was insensitive to all three heparinases,
while LR-166K, LR-168K, LR-55R, LR-159R and LR-82R were
partially sensitive to Hep I, highly sensitive to Hep II and partially
sensitive to Hep III. Notably, LR-79K was significantly more
sensitive to Hep I and Hep III than the other E2 mutants. LR-
D166E, again, exhibited an intermediate dependence phenotype
with all three heparinases. SINV-K70, in comparison, was highly
sensitive to all three heparinases, again suggesting differences in
GAG interactions between SINV and CHIKV mutants. In
contrast with these assays, blocking of infectivity by reaction of
virus particles with soluble heparin clearly distinguished LR-166K,
LR-82R and LR-79K from the other viruses. Small plaque size
and lack of change in size with addition of heparin to the overlay
provided a similar distinction.
Comparison of location in an electrostatic map of the CHIKV
heterotrimeric spike complex revealed that mutations that were
more attenuating to disease in mice appeared to create additional
positive charge that was more exposed to the exterior of the spike
(e.g., E2-79K, E2-82R and E2-166K as opposed to E2-55R, E2-
D166E or E2-159R). The lack of any attenuating phenotype with
E2- E2-D166E was surprising, especially since the electrostatic
model of this mutant suggested that the deletion should lead to
increased electrostatic potential of E2 similar to that of the other
E2 amino acid substitution mutants listed in Table 1 which
demonstrated various degrees of attenuation. Clearly, the inter-
pretation of the electrostatic potential maps of particular E2
mutant proteins will depend upon confirmation with in vitro
assessment of GAG dependency.
Our data for the E2-166K mutation, which we tested because of
its identical location to the selected E2-D166E mutation, indicate
that it confers efficient attachment to HS. This mutation was
selected by passage in a context where the authors concluded that
the mutation increased virus resistance to the OAS3 antiviral
protein, possibly by conferring a rapid entry phenotype [36].
Many of the HS-binding E2 mutants for SINV and VEEV were
originally selected and identified as rapid entry mutants and only
later shown to confer efficient HS binding [17,24,69–72]. The
relationship of HS binding, rapid entry and antiviral resistance is
unclear. However, if the LR-166K virus effectively antagonized
the antiviral response as suggested by Henrik Gad et al. [36], one
would expect the virus to be more virulent in vivo instead of more
attenuated compared to CHIKV-LR and thus this phenotype may
be an in vitro artifact or a localized phenomenon.
Overall, our data suggest that positively charged amino acid
substitutions in CHIKV E2 that result in small plaques and
efficient competition with heparin will be highly attenuated in the
adult mouse model of MSD. The LR-166K, LR-82R and LR-79K
viruses were very similar in terms of the primary in vitro correlates
of attenuation: plaque size and heparin sensitivity. In addition,
LR-79K was dramatically more attenuated for MSD than LR-
82R in the severely immunocompromised STAT1-deficient mice.
Testing in this model will refine choices between mutants with
similar in vitro characteristics and sensitivity to all three heparinases
may indicate the highest degree of in vivo attenuation within this
group. Furthermore, combinations of such mutations can be tested
to improve immunogenicity and/or stabilize attenuation. One
question raised by these studies is whether or not this paradigm for
deliberate mutation selection will be applicable to other alpha-
viruses and/or other arboviruses. We have detected differences
between SINV and CHIKV mutants in dependency upon HS
versus other GAGs for infectivity and it is unclear how this
phenotype correlates with attenuation in vivo especially when
evaluating the results of assays that are not specific to a particular
GAG. It is likely that the specific combination of in vitro assays most
correlated with attenuation must be determined for each virus
type.
In summation, these studies demonstrate that very limited
passage of CHIKV is sufficient to generate HS binding mutations
that are highly attenuating but retain immunogenicity, and would
make satisfactory candidates for testing in a LAV. Furthermore,
using this approach, we have identified E2-79K as a single site
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mutation that is highly attenuating for MSD and stable even in a
severely immunocompromised model of disease. It is possible that
attenuating mutations present in other areas of vaccine genomes
(e.g., nonstructural or non-translated region mutations in the YFV
17D vaccine or the VEEV TC83 vaccine [73]) would require
further passage to accrue. Therefore, rational LAV creation may
benefit from multiple selection strategies with an initial screen
identifying mutants meeting the criteria we have outlined for HS
binding-mediated attenuation followed by additional passage on
the same cell type or others or introduction of mutations identified
with other alphaviruses that could be reasonably transferred to
CHIKV.
Supporting Information
Figure S1 HS-dependent infectivity of CHIKV E2 mu-
tants. CHIKV E2 mutants were evaluated for dependency on HS
for infectivity by infectivity on cells deficient in either GAGs or
HS. (A) CHOK1, pgsA745 (GAG negative) and pgsD677 (HS
negative) cells were infected with virus and at 24 h p.i. fixed with
4% PFA and stained for CHIKV antigen. Percent infection on
pgsA745 and pgsD677 cells was normalized to infectivity on
CHOK1 cells that was set to 100%. Error bars represent standard
deviation. *p,0.001 compared to CHOK1 cells.
(TIF)
Figure S2 Attenuation of CHIKV E2 mutants in immu-
nocompromised mouse model. The most attenuated
CHIKV-E2 mutants in 21d CD1 mice were further tested for
attenuation in an immunocompromised mouse model. STAT129
mice (n = 4–5) were infected subcutaneously in the rear footpad
with either 105 genome equivalents of either (A) CHIKV-LR, (B)
LR-82R or (C) LR-79K. The metatarsal region (height and width)
was measured daily and fold change was calculated based on pre-
infection footpad area. Individual mice are graphed with the
intensity of shading indicates the proportion of mice with
overlapping levels of hind-limb swelling.
(TIF)
Table S1 Serum cytokine levels at two days post-
infection. p,0.05; **p,0.01; ***p,0.001; measured in pg/ml.
(DOCX)
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